Fresh analysis suggests that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who end conventional diet and exercise regimens.
Findings released in a major medical journal demonstrates that while obese individuals often shed substantial amounts of their body weight while undergoing treatment, the weight is regained at an estimated rate of nearly a kilo each month after stopping.
"Individuals purchasing these drugs should be cognizant of the danger of quick weight regain when the treatment concludes," warns lead investigator Dr. Susan Jebb.
That rate of recovery means a reversion to pre-treatment weight in about 18 months.
Comparing Treatments
The study, which looked at 37 of studies involving over 9,000 of patients, contrasted the results of the injectable medications with older methods.
Scientists note that people who lose weight through dieting generally see a more gradual creep back—around 0.1 kg a month—post-intervention.
Understanding the Fast Regain
Nutrition scientists propose the mode of action of the drugs accounts for the amplified weight return.
These medications mimic a body's own chemical called GLP-1, which controls hunger.
"Artificially providing GLP-1 levels far above than the body's typical production might result in the body to produce less of its own natural hormone, and could diminish responsiveness to its actions," said Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' results in appetite is uncontrolled, making excessive eating a significant risk."
A Chronic Issue?
The NHS recommend the injections for individuals with weight-linked medical conditions, alongside recommended lifestyle changes.
Many experts say that, given the likelihood of relapse, the therapy is often long-term.
This opinion is supported by pharmaceutical companies, who state that the findings "underscore the persistent character of obesity," similar to managing diseases like hypertension.
User Accounts
People who have stopped the jabs describe a powerful resurgence of hunger.
"It felt as if a trigger activating and you become extremely hungry," described one woman.
This difficulty is compounded if patients have not developed lasting dietary or behavioural modifications during treatment.
Growing Interest
Figures show that millions of people in the UK have tried these injections in the last 12 months, with desire remaining high.
- Adoption is greater among women compared to males.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Ultimately, experts caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone fix and lasting health benefits likely depends on combined behavioural support.
